Cargando…
Treatment outcome of anaplastic ependymoma under the age of 3 treated by intensity-modulated radiotherapy
PURPOSE: Intensity-modulated radiotherapy (IMRT) allows for more precise treatment, reducing unwanted radiation to nearby structures. We investigated the safety and feasibility of IMRT for anaplastic ependymoma patients below 3 years of age. MATERIALS AND METHODS: A total of 9 anaplastic ependymoma...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society for Radiation Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113147/ https://www.ncbi.nlm.nih.gov/pubmed/32229806 http://dx.doi.org/10.3857/roj.2020.00073 |
_version_ | 1783513606957039616 |
---|---|
author | Lee, Joongyo Chung, Seung Yeun Han, Jung Woo Kim, Dong-Seok Kim, Jina Moon, Jin Young Yoon, Hong In Suh, Chang-Ok |
author_facet | Lee, Joongyo Chung, Seung Yeun Han, Jung Woo Kim, Dong-Seok Kim, Jina Moon, Jin Young Yoon, Hong In Suh, Chang-Ok |
author_sort | Lee, Joongyo |
collection | PubMed |
description | PURPOSE: Intensity-modulated radiotherapy (IMRT) allows for more precise treatment, reducing unwanted radiation to nearby structures. We investigated the safety and feasibility of IMRT for anaplastic ependymoma patients below 3 years of age. MATERIALS AND METHODS: A total of 9 anaplastic ependymoma patients below 3 years of age, who received IMRT between October 2011 and December 2017 were retrospectively reviewed. The median equivalent dose in 2 Gy fractions was 52.0 Gy (range, 48.0 to 60.0 Gy). Treatment outcomes and neurologic morbidities were reviewed in detail. RESULTS: The median patient age was 20.9 months (range, 12.1 to 31.2 months). All patients underwent surgery. The rates of 5-year overall survival, freedom from local recurrence, and progression-free survival were 40.6%, 53.3%, and 26.7%, respectively. Of the 9 patients, 5 experienced recurrences (3 had local recurrence, 1 had both local recurrence and cerebrospinal fluid [CSF] seeding, and 1 had CSF seeding alone). Five patients died because of disease progression. Assessment of neurologic morbidity revealed motor dysfunction in 3 patients, all of whom presented with hydrocephalus at initial diagnosis because of the location of the tumor and already had neurologic deficits before radiotherapy (RT). CONCLUSION: Neurologic morbidity is not caused by RT alone but may result from mass effects of the tumor and surgical sequelae. Administration of IMRT to anaplastic ependymoma patients below 3 years of age yielded encouraging local control and tolerable morbidities. High-precision modern RT such as IMRT can be considered for very young patients with anaplastic ependymoma. |
format | Online Article Text |
id | pubmed-7113147 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Korean Society for Radiation Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-71131472020-04-07 Treatment outcome of anaplastic ependymoma under the age of 3 treated by intensity-modulated radiotherapy Lee, Joongyo Chung, Seung Yeun Han, Jung Woo Kim, Dong-Seok Kim, Jina Moon, Jin Young Yoon, Hong In Suh, Chang-Ok Radiat Oncol J Original Article PURPOSE: Intensity-modulated radiotherapy (IMRT) allows for more precise treatment, reducing unwanted radiation to nearby structures. We investigated the safety and feasibility of IMRT for anaplastic ependymoma patients below 3 years of age. MATERIALS AND METHODS: A total of 9 anaplastic ependymoma patients below 3 years of age, who received IMRT between October 2011 and December 2017 were retrospectively reviewed. The median equivalent dose in 2 Gy fractions was 52.0 Gy (range, 48.0 to 60.0 Gy). Treatment outcomes and neurologic morbidities were reviewed in detail. RESULTS: The median patient age was 20.9 months (range, 12.1 to 31.2 months). All patients underwent surgery. The rates of 5-year overall survival, freedom from local recurrence, and progression-free survival were 40.6%, 53.3%, and 26.7%, respectively. Of the 9 patients, 5 experienced recurrences (3 had local recurrence, 1 had both local recurrence and cerebrospinal fluid [CSF] seeding, and 1 had CSF seeding alone). Five patients died because of disease progression. Assessment of neurologic morbidity revealed motor dysfunction in 3 patients, all of whom presented with hydrocephalus at initial diagnosis because of the location of the tumor and already had neurologic deficits before radiotherapy (RT). CONCLUSION: Neurologic morbidity is not caused by RT alone but may result from mass effects of the tumor and surgical sequelae. Administration of IMRT to anaplastic ependymoma patients below 3 years of age yielded encouraging local control and tolerable morbidities. High-precision modern RT such as IMRT can be considered for very young patients with anaplastic ependymoma. The Korean Society for Radiation Oncology 2020-03 2020-03-25 /pmc/articles/PMC7113147/ /pubmed/32229806 http://dx.doi.org/10.3857/roj.2020.00073 Text en Copyright © 2020 The Korean Society for Radiation Oncology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lee, Joongyo Chung, Seung Yeun Han, Jung Woo Kim, Dong-Seok Kim, Jina Moon, Jin Young Yoon, Hong In Suh, Chang-Ok Treatment outcome of anaplastic ependymoma under the age of 3 treated by intensity-modulated radiotherapy |
title | Treatment outcome of anaplastic ependymoma under the age of 3 treated by intensity-modulated radiotherapy |
title_full | Treatment outcome of anaplastic ependymoma under the age of 3 treated by intensity-modulated radiotherapy |
title_fullStr | Treatment outcome of anaplastic ependymoma under the age of 3 treated by intensity-modulated radiotherapy |
title_full_unstemmed | Treatment outcome of anaplastic ependymoma under the age of 3 treated by intensity-modulated radiotherapy |
title_short | Treatment outcome of anaplastic ependymoma under the age of 3 treated by intensity-modulated radiotherapy |
title_sort | treatment outcome of anaplastic ependymoma under the age of 3 treated by intensity-modulated radiotherapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113147/ https://www.ncbi.nlm.nih.gov/pubmed/32229806 http://dx.doi.org/10.3857/roj.2020.00073 |
work_keys_str_mv | AT leejoongyo treatmentoutcomeofanaplasticependymomaundertheageof3treatedbyintensitymodulatedradiotherapy AT chungseungyeun treatmentoutcomeofanaplasticependymomaundertheageof3treatedbyintensitymodulatedradiotherapy AT hanjungwoo treatmentoutcomeofanaplasticependymomaundertheageof3treatedbyintensitymodulatedradiotherapy AT kimdongseok treatmentoutcomeofanaplasticependymomaundertheageof3treatedbyintensitymodulatedradiotherapy AT kimjina treatmentoutcomeofanaplasticependymomaundertheageof3treatedbyintensitymodulatedradiotherapy AT moonjinyoung treatmentoutcomeofanaplasticependymomaundertheageof3treatedbyintensitymodulatedradiotherapy AT yoonhongin treatmentoutcomeofanaplasticependymomaundertheageof3treatedbyintensitymodulatedradiotherapy AT suhchangok treatmentoutcomeofanaplasticependymomaundertheageof3treatedbyintensitymodulatedradiotherapy |